TY - JOUR
T1 - Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression
AU - Kasikara, Canan
AU - Kumar, Sushil
AU - Kimani, Stanley
AU - Tsou, Wen I.
AU - Geng, Ke
AU - Davra, Viralkumar
AU - Sriram, Ganapathy
AU - Devoe, Connor
AU - Nguyen, Khanh Quynh N.
AU - Antes, Anita
AU - Krantz, Allen
AU - Rymarczyk, Grzegorz
AU - Wilczynski, Andrzej
AU - Empig, Cyril
AU - Freimark, Bruce
AU - Gray, Michael
AU - Schlunegger, Kyle
AU - Hutchins, Jeff
AU - Kotenko, Sergei V.
AU - Birge, Raymond B.
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/6
Y1 - 2017/6
N2 - Tyro3, Axl, and Mertk (collectively TAM receptors) are three homologous receptor tyrosine kinases that bind Vitamin K- dependent endogenous ligands, Protein S (ProS), and growth arrest-specific factor 6 (Gas6), and act as bridging molecules to promote phosphatidylserine (PS)-mediated clearance of apoptotic cells (efferocytosis). TAM receptors are overexpressed in a vast array of tumor types, whereby the level of expression correlates with the tumor grade and the emergence of chemoand radioresistance to targeted therapeutics, but also have been implicated as inhibitory receptors on infiltrating myeloidderived cells in the tumor microenvironment that can suppress host antitumor immunity. In the present study, we utilized TAM-IFNγR1 reporter lines and expressed TAM receptors in a variety of epithelial cell model systems to show that each TAM receptor has a unique pattern of activation by Gas6 or ProS, as well as unique dependency for PS on apoptotic cells and PS liposomes for activity. In addition, we leveraged this system to engineer epithelial cells that express wild-type TAM receptors and show that although each receptor can promote PS-mediated efferocytosis, AKT-mediated chemoresistance, as well as upregulate the immune checkpoint molecule PD-L1 on tumor cells, Mertk is most dominant in the aforementioned pathways. Functionally, TAM receptor-mediated efferocytosis could be partially blocked by PS-targeting antibody 11.31 and Annexin V, demonstrating the existence of a PS/PS receptor (i.e., TAM receptor)/PD-L1 axis that operates in epithelial cells to foster immune escape. These data provide a rationale that PS-targeting, anti-TAM receptor, and anti-PD-L1-based therapeutics will have merit as combinatorial checkpoint inhibitors. Implications: Many tumor cells are known to upregulate the immune checkpoint inhibitor PD-L1. This study demonstrates a role for PS and TAM receptors in the regulation of PD-L1 on cancer cells.
AB - Tyro3, Axl, and Mertk (collectively TAM receptors) are three homologous receptor tyrosine kinases that bind Vitamin K- dependent endogenous ligands, Protein S (ProS), and growth arrest-specific factor 6 (Gas6), and act as bridging molecules to promote phosphatidylserine (PS)-mediated clearance of apoptotic cells (efferocytosis). TAM receptors are overexpressed in a vast array of tumor types, whereby the level of expression correlates with the tumor grade and the emergence of chemoand radioresistance to targeted therapeutics, but also have been implicated as inhibitory receptors on infiltrating myeloidderived cells in the tumor microenvironment that can suppress host antitumor immunity. In the present study, we utilized TAM-IFNγR1 reporter lines and expressed TAM receptors in a variety of epithelial cell model systems to show that each TAM receptor has a unique pattern of activation by Gas6 or ProS, as well as unique dependency for PS on apoptotic cells and PS liposomes for activity. In addition, we leveraged this system to engineer epithelial cells that express wild-type TAM receptors and show that although each receptor can promote PS-mediated efferocytosis, AKT-mediated chemoresistance, as well as upregulate the immune checkpoint molecule PD-L1 on tumor cells, Mertk is most dominant in the aforementioned pathways. Functionally, TAM receptor-mediated efferocytosis could be partially blocked by PS-targeting antibody 11.31 and Annexin V, demonstrating the existence of a PS/PS receptor (i.e., TAM receptor)/PD-L1 axis that operates in epithelial cells to foster immune escape. These data provide a rationale that PS-targeting, anti-TAM receptor, and anti-PD-L1-based therapeutics will have merit as combinatorial checkpoint inhibitors. Implications: Many tumor cells are known to upregulate the immune checkpoint inhibitor PD-L1. This study demonstrates a role for PS and TAM receptors in the regulation of PD-L1 on cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=85019883801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019883801&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-16-0350
DO - 10.1158/1541-7786.MCR-16-0350
M3 - Article
C2 - 28184013
AN - SCOPUS:85019883801
SN - 1541-7786
VL - 15
SP - 753
EP - 764
JO - Cell Growth and Differentiation
JF - Cell Growth and Differentiation
IS - 6
ER -